14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
LCTX vs DNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DNA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)
DNA Overall Winner
6-Pillar Tally: LCTX 2 – 3 DNA (1 Tie)
Matrix Metrics: LCTX 6 – 4 DNA
As of Nov 19, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas DNA carries 58.4/100 (HOLD) at $8.20 (N/M Forward P/E, -202.5% operating margin).
Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile DNA is in a Breakdown options structure phase (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
DNA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $547.1M market capitalization and -202.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LCTX vs DNA Key Questions & Quantitative Answers
As of Nov 19, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas DNA carries 58.4/100 (HOLD) at $8.20 (N/M Forward P/E, -202.5% operating margin). Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile DNA is in a Breakdown options structure phase (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DNA leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with DNA at -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while DNA shifted +240.0%. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNA.
LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus DNA (-58.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, DNA carries 104.1% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.12β · 149% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.